Mark A. Marzinke - Concepedia

Author

Mark A. Marzinke

Also Known As

Adeyeye, Adeola, C. W. Hendrix, Craig W. Hendrix, Fields, Sheldon D., Fogel, J.M., Hendrix, Craig W, Lara Kidoguchi, Lucas, Jonathan P, M A Marzinke, M Marzinke

297

Publications

10.3K

Citations

H-Index

123

Concepts

All Affiliations

Johns Hopkins University Johns Hopkins Medicine Fred Hutch Cancer Center Family Health International 360 National Institute of Allergy and Infectious Diseases

About

Mark A. Marzinke is an author at Johns Hopkins University specializing in medicine, hiv, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	42	2.6K
2	Social Sciences	9	9	680
3	Public Health	8	8	456
4	Engineering	4	4	170
5	Biochemistry	3	3	80

Mark A. Marzinke

147

Publications

Citations

H-Index

Page 1

	Year	Citations
Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women Jeanne Marrazzo, Gita Ramjee, Barbra A. Richardson, New England Journal of Medicine	2015	1.3K
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, New England Journal of Medicine	2021	773
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial Sinéad Delany‐Moretlwe, James P. Hughes, Peter Bock, The Lancet Sexual HealthPhase 3Treatment And PreventionHuman RetrovirusAntiviral Therapy	2022	498
Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women Jared M. Baeten, Thesla Palanee‐Phillips, Elizabeth R. Brown, Obstetrical & Gynecological Survey GynecologySocial SciencesHiv-1 Infection IncidenceContraceptionHiv/aids Counselling	2016	373
Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1–Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda Jared M. Baeten, Renee Heffron, Lara Kidoguchi, PLoS Medicine	2016	202
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066) Craig W. Hendrix, Adriana Andrade, Namandjé N. Bumpus, AIDS Research and Human Retroviruses	2015	173
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial Raphael J. Landovitz, Sue Li, Beatriz Grinsztejn, PLoS Medicine	2018	164
Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis Manjula Gunawardana, Mariana Remedios-Chan, Christine S. Miller, Antimicrobial Agents and Chemotherapy	2015	162
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial Raphael J. Landovitz, Sue Li, Joseph J. Eron, The Lancet HIV Treatment And PreventionPharmacologyAntiviral Drug DevelopmentAntiviral TherapyPharmacotherapy	2020	159
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083 Mark A. Marzinke, Beatriz Grinsztejn, Jessica M. Fogel, The Journal of Infectious Diseases	2021	120

Page 1